Bonne-Andréa C, Tillier F, McShan G D, Wilson V G, Clertant P
INSERM U470, Centre de Biochimie, University of Nice, France.
J Virol. 1997 Sep;71(9):6805-15. doi: 10.1128/JVI.71.9.6805-6815.1997.
We previously devised cell-free conditions supporting efficient replication of bovine papillomavirus type 1 (BPV1) DNA (C. Bonne-Andréa, S. Santucci, and P. Clertant, J. Virol. 69:3201-3205, 1995): the use of highly active preparations of viral initiator protein E1, together with extract from a particular cell source, allowed the synthesis of complete DNA circles through successive rounds of replication; this occurred in the absence of the viral transcriptional activator E2, required in vivo for the replication of viral genomes. We now report that adding E2 to cell-free assays produced only slight effects both on the yield of E1-dependent DNA synthesis and on the quality of newly made DNA molecules when a template carrying a wild-type BPV1 replication origin (ori) was used. The performance of mouse cell extracts, unable to sustain efficient BPV1 DNA replication in the presence of E1 only, was likewise not improved by the addition of E2. In a proper in vitro environment, E1 is thus fully capable of efficiently initiating viral DNA synthesis by itself, an activity which is not enhanced by interaction with E2. An important effect, however, was detected: E2 totally suppressed the nonspecific replication of ori-defective DNA templates, otherwise observed in high E1 concentrations. We examined the requirements for building a minimal DNA sequence behaving in vitro as a specific ori sequence under stringent recognition conditions, i.e., in the presence of both E1 and E2. Only two elements, the 18-bp E1 binding palindrome and an AT-rich sequence, were required in cis to allow specific cell-free DNA replication; there seemed to be no need for an E2 binding site to ensure discrimination between specific ori templates and other DNA molecules, even in the presence of E2. This suggests that during the initiation of BPV1 DNA replication, at least in vitro, E2 acts as a specificity factor restricting the action of E1 to a defined ori sequence; this function, likely not demanding the direct binding of E2 to cognate DNA sites, might primarily involve protein-protein interactions.
我们之前设计了支持牛乳头瘤病毒1型(BPV1)DNA高效复制的无细胞条件(C. Bonne-Andréa、S. Santucci和P. Clertant,《病毒学杂志》69:3201 - 3205,1995年):使用高活性的病毒起始蛋白E1制剂,连同来自特定细胞来源的提取物,可通过连续多轮复制合成完整的DNA环;这一过程在没有病毒转录激活因子E2的情况下发生,而E2在体内是病毒基因组复制所必需的。我们现在报告,当使用携带野生型BPV1复制起点(ori)的模板时,在无细胞检测中添加E2对依赖E1的DNA合成产量和新合成DNA分子的质量仅产生轻微影响。仅在E1存在时无法维持高效BPV1 DNA复制的小鼠细胞提取物,添加E2后其性能同样没有改善。因此,在合适的体外环境中,E1自身完全能够高效启动病毒DNA合成,这种活性不会因与E2相互作用而增强。然而,检测到一个重要影响:E2完全抑制了ori缺陷型DNA模板的非特异性复制,否则在高E1浓度下会观察到这种非特异性复制。我们研究了构建一个在严格识别条件下(即在E1和E2都存在时)在体外表现为特定ori序列的最小DNA序列的要求。顺式作用仅需要两个元件,即18碱基对的E1结合回文序列和一个富含AT的序列来允许特定的无细胞DNA复制;即使在有E2存在的情况下,似乎也不需要E2结合位点来确保区分特定ori模板和其他DNA分子。这表明在BPV1 DNA复制起始过程中,至少在体外,E2作为一种特异性因子,将E1的作用限制在定义的ori序列上;这种功能可能不要求E2直接结合到同源DNA位点,可能主要涉及蛋白质 - 蛋白质相互作用。